HOUSTONAfter controlling for socioeconomic status (SES) and treatment, African-Americans have only a marginally increased risk of death from colorectal cancer, according to a meta-analysis. Its authors suggest that efforts to eliminate socioeconomic and healthcare inequalities would significantly reduce the disease's mortality gap between blacks and whites. "Only a handful of studies have addressed racial disparities in survival for colon cancer by adequately incorporating both treatment and SES, in addition to factors on stage, grade, and co-morbidity," said Xianglin L. Du, MD, PhD, who conducted the study with colleagues from the School of Public Health, University of Texas Health Sciences Center at Houston. The report (on-line at DOI: 10.1002/cncr.22668) will appear in the June issue of Cancer.
The authors aggregated and analyzed data from 10 studies of colorectal cancer patients in which the investigators had adjusted for SES and treatment, and then focused on the association between race/ethnicity and surviving colorectal cancer.The pooled hazard ratio (HR) for blacks vs whites was 1.14 for all-cause mortality and 1.13 for colon-cancer-specific mortality. The test of homogeneity of HR was significant across the nine studies of all-cause mortality but not across the five studies of colon-cancer-specific mortality. The study showed that racial differences in colon cancer survival largely result from racial differences in SES, Dr. Du said, and that "the marginal remaining disadvantages for African-Americans are likely to be explained by factors related to low SES."
Social Factors Likely Explain Colon Ca Racial Disparities
After controlling for socioeconomic status (SES) and treatment, African-Americans have only a marginally increased risk of death from colorectal cancer, according to a meta-analysis.
HOUSTONAfter controlling for socioeconomic status (SES) and treatment, African-Americans have only a marginally increased risk of death from colorectal cancer, according to a meta-analysis. Its authors suggest that efforts to eliminate socioeconomic and healthcare inequalities would significantly reduce the disease's mortality gap between blacks and whites. "Only a handful of studies have addressed racial disparities in survival for colon cancer by adequately incorporating both treatment and SES, in addition to factors on stage, grade, and co-morbidity," said Xianglin L. Du, MD, PhD, who conducted the study with colleagues from the School of Public Health, University of Texas Health Sciences Center at Houston. The report (on-line at DOI: 10.1002/cncr.22668) will appear in the June issue of Cancer.
The authors aggregated and analyzed data from 10 studies of colorectal cancer patients in which the investigators had adjusted for SES and treatment, and then focused on the association between race/ethnicity and surviving colorectal cancer.The pooled hazard ratio (HR) for blacks vs whites was 1.14 for all-cause mortality and 1.13 for colon-cancer-specific mortality. The test of homogeneity of HR was significant across the nine studies of all-cause mortality but not across the five studies of colon-cancer-specific mortality. The study showed that racial differences in colon cancer survival largely result from racial differences in SES, Dr. Du said, and that "the marginal remaining disadvantages for African-Americans are likely to be explained by factors related to low SES."
COVID-19 Pandemic Has Exacerbated CRC Surgery Disparities
April 17th 2024Patients who are African American appeared to have worse clinical stages of colon and rectal cancer during surgery in 2020.
Joleen Hubbard, MD, Highlights The “Exciting Space” Of Metastatic CRC
December 11th 2023New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.
Blood-Based Test May Help Detect CRC in Average-Risk Population
April 7th 2024The PREEMPT trial analyzed samples from 27,010 average-risk adults to determine the specificity of detecting colorectal cancer.
Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment
November 27th 2023Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.
Personalized Vaccine Yields Early PFS Benefit in Metastatic MSS-CRC
April 2nd 2024Long-term circulating tumor DNA responses appear to align with progression-free survival trends in a phase 2/3 trial of the GRANITE vaccine in those with microsatellite-stable colorectal cancer.
Microbiome Signature Differences May Impact Rectal Cancer Treatment Effect
March 30th 2024Gut microbiome signatures may lead the way for more accurate treatments and diagnoses for patients with colorectal cancer.
COVID-19 Pandemic Has Exacerbated CRC Surgery Disparities
April 17th 2024Patients who are African American appeared to have worse clinical stages of colon and rectal cancer during surgery in 2020.
Joleen Hubbard, MD, Highlights The “Exciting Space” Of Metastatic CRC
December 11th 2023New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.
Blood-Based Test May Help Detect CRC in Average-Risk Population
April 7th 2024The PREEMPT trial analyzed samples from 27,010 average-risk adults to determine the specificity of detecting colorectal cancer.
Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment
November 27th 2023Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.
Personalized Vaccine Yields Early PFS Benefit in Metastatic MSS-CRC
April 2nd 2024Long-term circulating tumor DNA responses appear to align with progression-free survival trends in a phase 2/3 trial of the GRANITE vaccine in those with microsatellite-stable colorectal cancer.
Microbiome Signature Differences May Impact Rectal Cancer Treatment Effect
March 30th 2024Gut microbiome signatures may lead the way for more accurate treatments and diagnoses for patients with colorectal cancer.